Jun 2026 (Q2 FY26) — Aug 6, 2026
Lineage Cell Therapeutics Q2 FY26 — Pipeline Expansion and Manufacturing Prowess
Read the full callLineage Cell Therapeutics (LCTX) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Lineage Cell Therapeutics earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 1.1 | −61.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -834.7 | −119.3 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 1.5 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$0.95 −3.06% · −$0.03
Performance −42.4% 1Y
1Y: $1.65 on 17 Oct 2025 → $0.95. High $1.96 (3 Nov 2025), low $0.9 (1 Oct 2026).
- Previous close
- $0.98
- 52-week range
- $0.9 – $1.96
- One year
- −42.07%
Overview
- Symbol
- LCTX
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Lineage Cell Therapeutics earnings calls (LCTX)
Financials
What the filings say
Net profit, year on year: +105% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 4 | 3 | 2 | 3 | 4 | 7 | 2 | 1 |
| Expenses | 8 | 8 | 8 | 23 | 7 | 13 | 9 | 10 |
| Operating profit | -4 | -5 | -7 | -20 | -4 | -7 | -8 | -9 |
| Operating margin | −101.6% | −178.2% | −433.1% | −715.4% | −102.8% | −99.1% | −440.2% | −834.7% |
| Other income | 1 | 2 | 2 | -11 | -26 | 2 | 3 | 10 |
| Profit before tax | -3 | -3 | — | — | — | — | — | — |
| Tax rate | 0.0% | 0.0% | — | — | — | — | — | — |
| Net profit | -3 | -3 | -4 | -30 | -30 | 1 | -5 | 1 |
| EPS ($ per share) | -0.02 | — | -0.02 | -0.13 | -0.13 | — | -0.02 | 0.01 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 354 | 387 | 394 | 435 | 440 | 451 | 485 | 515 |
| Reserves | -262 | -273 | -294 | -337 | -363 | -385 | -403 | -467 |
| Total liabilities | 9 | 14 | 13 | 84 | 52 | 39 | 36 | 69 |
| Fixed assets | 6 | 8 | 6 | 5 | 6 | 2 | 2 | 3 |
| Investments | 7 | 21 | 9 | 3 | 47 | 0 | 2 | 15 |
| Total assets | 102 | 125 | 108 | 175 | 124 | 101 | 113 | 113 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -31 | -32 | -20 | -24 | 1 | -29 | -23 | -19 |
| Cash from investing | 12 | 17 | 13 | 10 | -46 | 46 | -2 | -13 |
| Cash from financing | 6 | 1 | 30 | 37 | 2 | 6 | 36 | 27 |
| Net cash flow | -13 | -14 | 23 | 23 | -44 | 24 | 10 | -5 |
| Capital expenditure | -1 | -0 | -0 | -0 | -0 | -1 | -1 | -1 |
| Free cash flow | -31 | -32 | -20 | -24 | 1 | -29 | -24 | -19 |
Insider filings
9 filings between Dec 19, 2025 and Mar 12, 2026.
Open market
decisions to buy or sellPurchases
$24.4K
1 purchase by 1 insider
Sales
None
No insider sold shares.
Compensation
not trading decisions- 2
- Award — granted as compensation
- 2
- Option exercise — converted options into shares
- 4
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Culley Brian M | $24.4K | — | Mar 12, 2026 |
Latest filings (19)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Mar 12, 2026 | Culley Brian M President and CEO | Purchase | 15,000 | $24.4K |
| Feb 11, 2026 | Samuel George A. III General Counsel and Secretary | Option exercise | 6,075 | — |
| Feb 11, 2026 | Samuel George A. III General Counsel and Secretary | Tax withheld | 2,502 | $4.5K |
| Feb 11, 2026 | Culley Brian M President and CEO | Option exercise | 31,250 | — |
| Feb 11, 2026 | Culley Brian M President and CEO | Tax withheld | 12,869 | $23.2K |
| Dec 19, 2025 | Samuel George A. III General Counsel and Secretary | Award | 1,735 | — |
| Dec 19, 2025 | Samuel George A. III General Counsel and Secretary | Tax withheld | 65 | $109 |
| Dec 19, 2025 | Culley Brian M President and CEO | Award | 8,925 | — |
| Dec 19, 2025 | Culley Brian M President and CEO | Tax withheld | 334 | $561 |
| Feb 11, 2025 | Culley Brian M President and CEO | Option exercise | 31,249 | — |
| Feb 11, 2025 | Culley Brian M President and CEO | Tax withheld | 12,547 | $8.2K |
| Feb 11, 2025 | Samuel George A. III General Counsel | Option exercise | 6,076 | — |
| Feb 11, 2025 | Samuel George A. III General Counsel | Tax withheld | 2,440 | $1.6K |
| Jan 27, 2025 | BROADWOOD PARTNERS, L.P. Director | Purchase | 7,894,737 | $6.00M |
| Jan 27, 2025 | BROADWOOD PARTNERS, L.P. Director | Purchase | 0 | $0 |
| Nov 26, 2024 | Samuel George A. III General Counsel | Purchase | 15,000 | $9.0K |
| Nov 26, 2024 | Howe Jill Ann Chief Financial Officer | Purchase | 15,000 | $8.8K |
| Nov 22, 2024 | Mulroy Michael H. Director | Purchase | 40,000 | $22.6K |
| Nov 21, 2024 | Culley Brian M President and CEO | Purchase | 40,000 | $24.0K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Lineage Cell Therapeutics, Inc.
Free account. Everything above stays public.
Write why you follow Lineage Cell Therapeutics, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading